The Company ended the quarter with $48.4 million in cash and investments. On September 30, 2024, the Company closed an offering raising approximately $13.6 million net cash proceeds. Based on management’s current expectations, this capital has the potential to fund the Company through several significant milestones, including filing the anticipated FDA pre-market approval of the VenoValve, the beginning of preparations for VenoValve commercialization, and the beginning of the enVVe pivotal trial.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on NVNO:
- enVVeno Medical initiates six-month pre-clinical GLP study of enVVe
- enVVeno Medical 4.3M share Spot Secondary priced at $3.50
- enVVeno Medical offers to sell common stock
- enVVeno Medical appoints Sandy Prietto as VP, marketing
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
